focus -WSS

focus

author：Wikipedia 2025-09-03 18:36:01 - browse：3128

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The benefits and risks of Eli Lilly’s treatment for Alzheimer’s disease were confirmed in detailed scientific disclosures Monday, paving the way for its full approval but leaving physicians with lingering questions about the medicine’s impact on patients as a new era in Alzheimer’s therapy unfolds.

The drug, called donanemab, showed a 35% slowing of Alzheimer’s disease progression relative to placebo in a clinical trial that enrolled 1,700 patients with early-stage disease. Numerically, that’s a modest, 3.3-point improvement on a 144-point survey, called the Integrated Alzheimer’s Disease Rating Scale, or iADRS, that combines measures of cognition and function, such as driving, managing finances, or carrying on conversations.

There was a similar benefit when donanemab’s efficacy was assessed using a more common measure of cognition called the Clinical Dementia Rating-Sum of Boxes, or CDR-SB. On that scale, the Lilly drug showed a 36% slowing of cognitive decline relative to placebo, or 0.68 points on an 18-point scale.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： How to bring more disabled researchers into academia

focus

WSS

Headspace, Meta partner to launch VR meditation app for Quest

Change Healthcare cyberattack prompts Medicare loan program

A preacher's new calling: Diversifying neuroscience research

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

Amylyx ALS drug failure raises questions and concerns

American taxpayers paid $1.8 trillion in health care costs in 2022

focus

focus

leisure time

Hepatitis C has a cure — but many Americans still lack access to it

With psoriasis trial ahead, Alumis raises $259 million

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Amylyx ALS drug failure raises questions and concerns

New air purifier tech could be key to improving indoor air quality

American taxpayers paid $1.8 trillion in health care costs in 2022

Medical records are filled with copy

In his State of the Union, Biden takes clear aim at 'Big Pharma'

How one medical school became remarkably diverse

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

entertainment

Medicare Advantage overpayments discussion gets experts fired up

In shift, Texas to cover initial consult for Afghan baby's gene therapy

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

Medicare Advantage overpayments discussion gets experts fired up

Allen Institute goes after foundational questions, CEO Costa says

Merck to acquire Harpoon Therapeutics for $680 million

focus

entertainment

explore

focus